Histogen is a leading drug development company focused on revolutionizing immunotherapy. Managed by highly successful biotech industry veterans, we specialize in restoring the competence of the immune system to effectively combat infectious diseases. Our innovative approach involves developing cutting-edge small molecule inhibitors that restore the body's natural immune processes.

Our product candidates include emricasan, CTS-2090, and other proprietary caspase inhibitors. Emricasan, extensively studied in multiple clinical trials involving over 1000 subjects, effectively reduces inflammation and disease-driven cell damage. It has shown promise in eradicating MRSA bacterial skin infections by a novel host-mediated mechanism of action.

CTS-2090, another novel inhibitor, targets inflammatory caspases and has demonstrated potency in models of ulcerative colitis and bacterial infections in the gastrointestinal tract. At Histogen, we are committed to bringing life-changing options to redefine immunotherapy. With our game-changing solutions and expertise, we aim to provide innovative treatments for infectious and inflammatory diseases.

Learn more about our science and our mission to combat antibiotic resistance through non-antibiotic solutions. Contact us to discover how our cutting-edge research can make a difference in the world of immunotherapy